Considerations When Managing HR+/HER2- Breast Cancer With CDK4/6 Inhibitors

Share

Program Content

  • Considerations When Managing HR+/HER2- Breast Cancer With CDK4/6 Inhibitors
    Considerations When Managing HR+/HER2- Breast Cancer With CDK4/6 Inhibitors
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022
    View Activity

Faculty

cover img faculity

Julia LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California